'MOLTO', A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON VENETOCLAX, ATEZOLIZUMAB, OBINUTUZUMAB (AVO) COMBINATION IN RICHTER TRANSFORMATION: SAFETY INTERIM ANALYSIS

Autor: Frustaci, AM, Tedeschi, A, Zinzani, PL, Pietrasanta, D, Coscia, M, Zenz, T, Motta, M, Gaidano, G, Scarfo, L, Deodato, M, Zamprogna, G, Vitale, C, Cairoli, R, Rossi, D, Montillo, M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1299::e6b420b80f54e38a18dbd7141b03eac7
https://hdl.handle.net/10281/409342

Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape

Autor: Morelli, F, Innocenti, I, Autore, F, Fresa, F, Tomasso, A, Piciocchi, A, Frustaci, Am, Trentin, L, Mauro, Fr, Schiattone, L, Visentin, A, Del Poeta, G, Reda, G, Rigolin, Gm, Ibatici, A, Ciolli, S, Vitale, C, Sportoletti, P, Murru, R, Levato, L, Gentile, M, D’Arena, G, Coscia, M, Villa, Mr, Fontana, R, Efremov, D, Tedeschi, A, Scarfò, L, Cuneo, A, Foà, R, Laurenti, L

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______970::ef9cbecf954ffd11685c4b4cb4299941
http://hdl.handle.net/2318/1759574

A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS

Autor: Montillo, M, Rossi, D, Motta, M, Quaresmini, G, Rossi, M, Coscia, Marta, Anastasia, A, Rossini, F, Cortellezzi, A, Nador, G, Scarfo, L, Cairoli, R, Frustaci, Am, Dal Ceggio, D, Picardi, P, De Paoli, L, Orlandi, E, Rambaldi, A, Morra, E, Massaia, Massimo, Tedeschi, A.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::06e6aaabad702d3866115ab19eeeb404
https://hdl.handle.net/10281/410636

Fludarabine, cyclophosphamide and lenalidomide (FCL) for previously treatd patients with CLL. GIMEMA study CLL0606

Autor: Mauro, Fr, Armiento, D, Vignetti, M, De Propris MS, Nanni, M, Marinelli, M, Frustaci, Am, Orlando, S, Graziosi, A, Molica, M, Carella, Am, DEL GIUDICE, Ilaria, Guarini, A, Foà, R.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3686::668971b7ad2073222b51a0fcacf4e8a4
http://hdl.handle.net/11573/483735

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial.

Autor: Tedeschi A; Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy. Electronic address: alessandra.tedeschi@ospedaleniguarda.it., Frustaci AM; Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy., Condoluci A; Department of Oncology, Institute of Oncology Research, Bellinzona, Switzerland; Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland., Coscia M; Department of Oncology ASST Sette Laghi, Ospedale di Circolo, Varese, Italy., Chiarle R; Division of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy; Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy; Department of Pathology, Boston Children's Hospital, Boston, MA, USA., Zinzani PL; Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'L e A Seràgnoli', Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy., Motta M; SC Ematologia, ASST Spedali Civili, Brescia, Italy., Gaidano G; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy., Quaresmini G; Azienda Socio-Sanitaria Territoriale Papa Giovanni XXVIII, Bergamo, Italy., Scarfò L; Università Vita-Salute San Raffaele and IRCC Ospedale San Raffaele, Milan, Italy., Catania G; Division of Hematology, Azienda Ospedaliera SS Arrigo e Biagio e Cesare Arrigo, Alessandria, Italy., Deodato M; Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy., Jones R; University Division of Hematology, AOU Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy., Tabanelli V; Division of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy., Griggio V; University Division of Hematology, AOU Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy., Stüssi G; Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biomedical Science, Universita' della Svizzera Italiana, Lugano, Switzerland., Calleri A; Division of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy., Pini K; Department of Oncology, Institute of Oncology Research, Bellinzona, Switzerland., Cairoli R; Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy., Zenz T; Department of Medical Oncology & Hematology, University Hospital and University of Zürich, Zürich, Switzerland; The LOOP Zürich-Medical Research Center, Zürich, Switzerland., Signori A; Department of Health Science, University of Genoa, Genoa, Italy., Zucca E; Department of Oncology, Institute of Oncology Research, Bellinzona, Switzerland; Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biomedical Science, Universita' della Svizzera Italiana, Lugano, Switzerland., Rossi D; Department of Oncology, Institute of Oncology Research, Bellinzona, Switzerland; Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biomedical Science, Universita' della Svizzera Italiana, Lugano, Switzerland., Montillo M; Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Oct; Vol. 25 (10), pp. 1298-1309. Date of Electronic Publication: 2024 Sep 10.